retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide, a (GLP1, GIP, glucagon), just released 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Lilly's triple agonist achieves 16.8%
Pay in 4 interest-free payments of $5.72 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12




























